Diulcus® Approved for DFU in India: Ipca Partners with NovaLead

On August 6, 2024, NovaLead’s patented repurposed drug was approved by CDSCO for treating Diabetic Foot Ulcer (DFU) in the Indian market. Ipca Laboratories Ltd will market the drug under the brand name Diulcus.

The approval is based on a Phase III study showing that NovaLead’s patented drug, Diulcus®, helps close Diabetic Foot Ulcers (DFUs) much more effectively than the current standard treatment. DFUs are a major issue, affecting over 15% of diabetic patients at some point and leading to frequent lower limb amputations.

This approval is crucial as it provides a much-needed effective treatment for complete wound closure. Diulcus® achieved 20% better results in closing wounds compared to existing treatments. This approval also highlights successful collaboration between public and private sectors, as its development received partial funding from BIRAC, a Government of India initiative.

Diulcus® is a new topical formulation of an active ingredient initially used as an intravenous injection to treat Tachycardia. NovaLead has secured patents for Diulcus® in several countries, including major markets like the USA, EU, and Japan. Ipca will offer Diulcus® to Diabetic Foot Ulcer patients in India through an exclusive licensing agreement with NovaLead.

“We are delighted to partner with NovaLead through an IP licensing arrangement to bring Diulcus® to DFU patients in India. It demonstrates Ipca’s commitment towards the patients suffering from unmet medical needs of DFU management and its focus on the diabetes sector. We are lining up to make Diulcus® available in the Indian market starting in August 2024.” Said Mr Premchand Godha, Executive Chairman of Ipca Laboratories Ltd.’

About Diabetic Foot Ulcer (DFU)

Diabetic Foot Ulcer (DFU) is a major issue affecting people with diabetes. Currently, over 537 million adults have diabetes, and this number is expected to reach 643 million by 2030. About 15% of diabetics will experience DFU at least once, and 25% of these ulcers will require amputation. DFU is a leading cause of lower limb amputations, with a five-year mortality rate of 46% after amputation.

About Ipca Laboratories

Ipca is a fully integrated pharmaceutical company with a strong focus on exports. It operates with vertical integration, producing both Finished Dosage Forms (PDFs) and Active Pharmaceutical Ingredients (APIs). It is one of India’s top 20 pharmaceutical companies and stands out for its comprehensive approach.

On August 06, 2024, IPCA Laboratories Ltd’s share price opened at ₹1,288.30, touching the day’s high at ₹1,328.95 at 02:43 PM on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.